| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/04/2010 | US7709488 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-[4-(4-methylpiperazin-1-yl-sulfonyl)-phenyl]-3H-imidazo-[4,5-b]pyridine,; acute inflammatory diseases: Septic shock, sepsis, SIRS, hemorrhagic shock, organ transplantation and transplant rejection, head trauma, acute lung injury |
| 05/04/2010 | US7709486 antiviral compounds 1,4,8,11-tetraazacyclotetradecane derivatives for against HIV-infected cells, to inhibit the binding by the natural ligand to its chemokine receptor; viricides |
| 05/04/2010 | US7709480 2-(3,4-dichlorophenylamino)-4-thiocyanato-5-nitro-pyrimidine; 2-chloro-4-(2-acetylamino-ethylamino)-5-trifluoromethyl-pyrimidine; lung cancer |
| 05/04/2010 | US7709478 Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents |
| 05/04/2010 | US7709473 5-[2-(6-tert-Butyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-8-ylamino)-ethoxy]-nicotinic acid methyl ester; inhibitors of glycogen synthase kinase 3 (GSK-3); diabetes, dementia, Alzheimer's Disease, bipolar disorder, stroke, schizophrenia, depression, hair loss, cancer |
| 05/04/2010 | US7709466 Pyridazinone derivatives, methods for their production and their use as pharmaceuticals |
| 05/04/2010 | US7709460 co-administration of a glutathione precursor (N-acetyl cysteine or alpha -lipoic acid) and hydroxocobalamin (a derivative of Vitamin B12) to patients with a functional Vitamin B12 deficiency and suffering from a neuropsychiatric abnormality |
| 05/04/2010 | US7709459 Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis |
| 05/04/2010 | US7709255 Nerve cells obtained by the method of the present invention have the flexibility to differentiate into a variety of types of neurons in vivo preferably without the need for application of growth factors; Embryonic Stem (ES) cells |
| 05/04/2010 | US7709228 Single-chain polypeptide fusion comprising functional binding, translocation and clostridial neurotoxin heavy chain domain for use as therapeutic agents and/or transporter molecules |
| 05/04/2010 | US7709220 Methods of monitoring treatment of BAFF-R related disease |
| 05/04/2010 | US7709207 Method for identifying compounds for treatment of pain |
| 05/04/2010 | US7709020 Implantable device comprising phosphorus-containing macrolides |
| 05/04/2010 | US7708987 ras-mediated; administering immunosuppressive for immune constituents that may interfere with the systemic delivery of the reovirus; antiproliferative; in the neoplastic cells phosphorylation of PKR is prevented by inactivation or deletion of PKR; antitumor agents |
| 05/04/2010 | CA2455566C (+)-cycloolivil as antioxidant obtained from stereospermum personatum |
| 05/04/2010 | CA2448863C Increased and sustained in vivo gene expression using a nucleic acid, histone, and amphipathic compound composition |
| 05/04/2010 | CA2440419C Azacycloalkyl substituted acetic acid derivatives for use as mmp inhibitors. |
| 05/04/2010 | CA2437767C Heterocyclic inhibitors of erk2 and uses thereof |
| 05/04/2010 | CA2412789C Compositions for improving mental concentration |
| 05/04/2010 | CA2373856C 1-arylcycloalkyl sulphides, sulphoxides and sulphones for the treatment of drug misuse or addictive disorders |
| 05/04/2010 | CA2367636C Fusion proteins |
| 05/04/2010 | CA2350671C Riluzole and alpha-tocopherol combination |
| 05/04/2010 | CA2320467C Cycloalkene derivatives, their production and use |
| 05/04/2010 | CA2158134C Supplemented tissue sealant |
| 04/29/2010 | WO2010048446A2 Modulation of axon degeneration |
| 04/29/2010 | WO2010048273A2 Methods and compounds for treatment of neurodegenerative disorders |
| 04/29/2010 | WO2010048164A2 N,n'-di-p-bromophenyl guanidine treatment for stroke at delayed timepoints |
| 04/29/2010 | WO2010047372A1 2-aminopyridin-4-one and 2-aminopyridine derivative both having bace1-inhibiting activity |
| 04/29/2010 | WO2010047361A1 Pharmaceutical composition improved in absorption through intestinal tract |
| 04/29/2010 | WO2010047127A1 PHENANTHROINDOLIZIDINE COMPOUND AND NFκB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT |
| 04/29/2010 | WO2010047126A1 PHENANTHROINDOLIZIDINE DERIVATIVE AND NFκB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT |
| 04/29/2010 | WO2010046791A1 Phosphodiestarase inhibitors |
| 04/29/2010 | WO2010046710A1 Therapeutics for neurological disorders |
| 04/29/2010 | WO2010046706A1 Treatment of inflammatory disorders |
| 04/29/2010 | WO2010046399A1 Combinations for the treatment of migraine |
| 04/29/2010 | WO2010046109A1 Pyrimidine and triazine sulfonamide derivates as b1 bradykinin receptor (b1r) inhibitors for treating pain |
| 04/29/2010 | WO2010046108A1 Substituted 4,5,6,7-tetrahydrothienopyridines as kcnq2/3 modulators for treating pain, epilepsy and urinary incontinence |
| 04/29/2010 | WO2010045948A1 Isoquinolinone derivatives as nk3 antagonists |
| 04/29/2010 | WO2010045788A1 A orally disintegrating tablet of donepezil hydrochloride and the preparation method thereof |
| 04/29/2010 | WO2010011856A3 Stereospecificity of methylsulfinyl reduction |
| 04/29/2010 | WO2010007316A3 Novel triazolo(4,3-a)pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as met inhibitors |
| 04/29/2010 | WO2010006267A3 Cyclic tetrapeptides |
| 04/29/2010 | WO2009153428A3 Use of trilostane for treating depression |
| 04/29/2010 | WO2009021991A9 Use of r(+)-alpha-lipoic acid for cryptogenic neuropathy |
| 04/29/2010 | US20100105946 Hydrolytically Degradable Carbamate Derivatives of Poly(Ethylene Glycol) |
| 04/29/2010 | US20100105896 Pharmaceutical compounds |
| 04/29/2010 | US20100105779 Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain |
| 04/29/2010 | US20100105778 treating neuropathic pain with milnacipran or salt |
| 04/29/2010 | US20100105777 Amide or thioamide derivatives and their use in the treatment of pain |
| 04/29/2010 | US20100105774 Antidepressant |
| 04/29/2010 | US20100105761 Treatment of pain through expression of opioid receptors |
| 04/29/2010 | US20100105756 Method of Treating Down Syndrome |
| 04/29/2010 | US20100105755 Substituted benzamide modulators of dopamine receptor |
| 04/29/2010 | US20100105754 5-(4phenyl)prolinamide for treatment of epilepsy |
| 04/29/2010 | US20100105748 Methods and compositions for treatment of drug addiction |
| 04/29/2010 | US20100105736 N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles |
| 04/29/2010 | US20100105735 Small Volume Oral Transmucosal Dosage Forms Containing Sufentanil for Treatment of Pain |
| 04/29/2010 | US20100105730 Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine |
| 04/29/2010 | US20100105727 Novel benzamide derivatives and process for the prepartion thereof |
| 04/29/2010 | US20100105722 Substituted 4,5,6,7-tetrahydrothienopyridines as KCNQ2/3 Modulators |
| 04/29/2010 | US20100105721 IMIDAZO[1,2-a]PYRIDINE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS |
| 04/29/2010 | US20100105720 Preparation and utility of substituted imidazopyridine compounds with hypnotic effects |
| 04/29/2010 | US20100105715 Polymer conjugates of opioid antagonists |
| 04/29/2010 | US20100105713 GLYT1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders |
| 04/29/2010 | US20100105709 6-Butyl-2-methoxy-5-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-3-phenylpyrimidin-4(3H)-one; for hypertension, cardiac disease, arteriosclerosis, kidney disease, stroke, dyslipidemia, obesity, diabetes, nonalcoholic steatohepatitis, dementia and/or Alzheimer's disease in a mammal |
| 04/29/2010 | US20100105707 Method of treating or preventing oxidative stress-related disease |
| 04/29/2010 | US20100105704 7-(3',4'-Dialkoxyphenyl)-[1,2,4]-Triazolo[1,5-A]Pyrimidine Compounds, Process for Preparing Thereof, and Pharmaceutical Composition for Treating or Preventing Asthma, Chronic Obstructive Pulmonary Disease, Arthritis, Atopic Dermatitis, Tumor and Degenerative Brain Diseases Comprising the Same |
| 04/29/2010 | US20100105699 Crystalline base of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
| 04/29/2010 | US20100105697 Therapeutic agents |
| 04/29/2010 | US20100105696 IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND mTOR INHIBITORS |
| 04/29/2010 | US20100105694 Substituted pyrazinone derivatives for use as a medicine |
| 04/29/2010 | US20100105693 Modulators of Muscarinic Receptors |
| 04/29/2010 | US20100105689 Novel 1,4- and 1,5-diarylsubstituted 1,2,3-triazoles useful as potassium channel modulators |
| 04/29/2010 | US20100105688 Pharmaceutical compositions comprising 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazine or r(-)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine and an nk1 |
| 04/29/2010 | US20100105687 Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds |
| 04/29/2010 | US20100105682 Cyclopropyl-piperazine compounds as calcium channel blockers |
| 04/29/2010 | US20100105681 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors |
| 04/29/2010 | US20100105680 Substituted dimethylcyclobutyl compounds, their preparation and use in medicaments |
| 04/29/2010 | US20100105679 5-pyridinone substituted indazoles |
| 04/29/2010 | US20100105678 Novel anxiolytic compounds |
| 04/29/2010 | US20100105677 Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
| 04/29/2010 | US20100105672 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
| 04/29/2010 | US20100105666 Triazabenzo (a)naphtho(2,1,8-cde) azulene compounds. |
| 04/29/2010 | US20100105665 Renin inhibitors |
| 04/29/2010 | US20100105657 Compounds, Process for their Preparation, Intermediates, Pharmaceutical Compositions and their use in the Treatment of 5-HT6 Mediated Disorders such as Alzheimer's Disease, Cognitive Disorders, Cognitive Impairment Associated with Schizophrenia, Obesity and Parkinson's Disease |
| 04/29/2010 | US20100105651 Antagonists of sns sodium channels |
| 04/29/2010 | US20100105646 Allopregnanolone in a method for enhancing neurological function (alzheimer disease) |
| 04/29/2010 | US20100105634 Use of glucosamine as a mental and physical stress recovery enhancer and a performance enhancer |
| 04/29/2010 | US20100105631 Inositol Compounds and Uses of Same in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation or Amyloid Formation, Desposition, Accumulation or Persistence |
| 04/29/2010 | US20100105630 Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
| 04/29/2010 | US20100105623 Schizophrenia-related isoform of kcnh2 and development of antipsychotic drugs |
| 04/29/2010 | US20100105608 Peptides and methods using same for diagnosis and treatment of amyloid-associated disease |
| 04/29/2010 | US20100105603 Methods and Preparations For Curing Clinically Ill Patients |
| 04/29/2010 | US20100105601 Method for treating a synucleinopathy |
| 04/29/2010 | US20100104675 Method Of Treating Demyelinating Central Nervous System Diseases |
| 04/29/2010 | US20100104657 Pharmaceutical composition comprising a reduced concentration of cholesterol |
| 04/29/2010 | US20100104651 Pharmaceutical Compositions Containing Diacerein |
| 04/29/2010 | US20100104643 Pharmaceutical compositions |
| 04/29/2010 | US20100104639 Bupropion hydrobromide and therapeutic applications |
| 04/29/2010 | US20100104634 Pharmaceutical compositions of entacapone |